The invention relates to a pharmaceutical buccal, sublingual, gingival or intranasal formulation comprising Tadalafil or the salt thereof as an active substance, a polymer and a surfactant. The invention also relates to a method for producing said formulation and to the use thereof in a medicament for treating sexual dysfunction. The average particle size of the active substance is between 8 and 500nm and the polymer is polyvinylpyrrolidone (PVP) and/or vinylpyrrolidone-vinyl acetate copolymer (VP/VA). The surfactant can be, for example, sodium dodecyl sulfate (SDS). The maximum serum level of active ingredient is reached within just one hour after the medicament has been administered.
